Horizon's Upcoming Webinars - Register for FREE today - Limited Spaces Available

The following webcasts are scheduled. Participation is free, so please register to participate.

Please be aware that Webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start of the webinar to establish access.

Please click here to view our archived webcasts.

Using cell-based assays in the development of efficacious cancer therapies

Date: November 12th, 2014 16: 00-16: 30 GMT (London time)

Personalised medicine has changed the landscape of cancer drug discovery. Tools such as panels of isogenic cell lines, RNAi screening platforms and assays that mimic the tumour environment all contribute to greater understanding of disease and more accurate prediction of patient responses to drugs and drug combinations. At this free webinar, we will describe how Horizon Discovery Services can help you to answer key questions, including identification of on-target drug activity, identification of responsive or resistant patient populations, compound profiling and detailed mechanism of action studies, and effects of the tumour microenvironment on tumour growth and drug response (3D assay systems).

Register here for this Webinar

RNA-based screening in drug discovery – introducing sgRNA technologies

Date: December 9th, 2014 16: 00-16: 30 GMT (London time)

Horizon is a world-leader in genome-editing, and in this free webinar we discuss our approach to RNAi screening using siRNA and CRISPR-Cas9 sgRNA technologies. Topics will include introduction to RNAi technologies, use of X-MAN™ isogenic cell lines in RNAi screening approaches, comparison of siRNA and sgRNA screening approaches, possibilities and challenges of genome-wide CRISPR-Cas9 knockout (GeCKO) screening, and examples of synthetic lethal screenings using siRNA and CRISPR-Cas9 sgRNA technologies for target identification and patient stratification.

Register here for this Webinar

The Effect of Formalin on Clinical Diagnostics

Date: December 11th, 2014 16: 00-16: 40 GMT (London time)

The use of formalin fixative stems from its ability to cross-link proteins, however it has also been reported to induce methylol modifications and acid-mediated hydrolysis which can confound genotyping analysis. Similarly, variability in the fixation time, delay of fixation and type of fixation effect tumor biopsies and subsequent sequencing. Here, we present the design and validation of our Formalin-Compromised HDx Reference Standards with precisely defined molecular weights that mimic formalin-treated samples and their performance in assays. We will discuss the effects of formalin on clinical diagnostics and how these can be minimized.

Register here for this Webinar

​